1. Ross AH, Lencher E, Reitman G. Modification
of chickenpox in family contacts by administration of gamma globulin.
N
Engl J Med. 1962;267:369-376.
[PubMed: 14494142]
2. Seward JF, Zhang JX, Maupin TJ, Mascola L, Jumaan AO. Contagiousness
of varicella in vaccinated cases: a household contact study. JAMA.
2004;292(6):704-708.
3. Seward JF, Galil K, Wharton M. Epidemiology of varicella.
In: Arvin A, Gershon A, eds. Varicella-Zoster Virus: Virology and
Clinical Management. Cambridge: Cambridge University Press;
2000:187-205.
4. Brisson M, Edmunds WJ. Epidemiology of varicella-zoster virus
in England and Wales. J Med Virol. 2003;70(suppl
1):S9-S14.
5. Meyer P, Seward JF, Jumaan AO, Wharton M. Varicella mortality:
trends before vaccine licensure in the United States, 1970–1994.
J
Infect Dis. 2000;182:383-390.
[PubMed: 10915066]
6. Galil K, Brown C, Lin F, Seward J. Hospitalizations for varicella
in the United States, 1988–1999.
Pediatr Infect
Dis J. 2002;21(10): 931–935.
[PubMed: 12394815]
7. Davis MM, Patel MS, Gebremariam A. Decline in varicella-related
hospitalizations and expenditures for children and adults after
introduction of varicella vaccine in the United States. Pediatrics.
2004;114(3):786-792.
8. Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A. Impact
of varicella vaccination on health care utilization. JAMA.
2005;294(7):797-802.
9. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due
to varicella after implementation of varicella vaccination in the United
States.
N Engl J Med. 2005;352:450-458.
[PubMed: 15689583]
10. Chaves SS, Gargiullo P, Zhang JX, et al. Loss of vaccine-induced immunity
to varicella over time. N Engl J Med. 2007;356(11):1121-1129.
11. Feldman S, Epp E. Detection of viremia during incubation
period of varicella.
J Pediatr. 1979;94:746-748.
[PubMed: 221632]
12. Asano Y, Itakura N, Kajita Y, et al. Severity of viremia
and clinical findings in children with varicella.
J Infect
Dis. 1990;161:1095-1098.
[PubMed: 2161037]
13. Mainka C, Fuss B, Geiger H, Hofelmayr H, Wolff MH. Characterization
of viremia at different stages of varicella-zoster virus infection.
J
Med Virol. 1998;56:91-98.
[PubMed: 9700639]
14. Ku CC, Zerboni L, Ito H, Graham BS, Wallace M, Arvin AM. Varicella-zoster
virus transfer to skin by T cells and modulation of viral replication
by epidermal cell interferon-alpha. J Exp Med.
2004;200(7):917-925.
15. Chen J, Zhu Z, Gershon A, Gershon M. Dependence of the entry
and cell association of varicella zoster virus on the cation-independent
mannose 6-phosphate receptor in vitro and in the skin of human patients
with varicella and zoster.
Cell. 2004;119:915-926.
[PubMed: 15620351]
16. Zhu Z, Gershon MD, Gabel C, Sherman D, Ambron R, Gershon AA.
Entry and egress of VZV: role of mannose-6-phosphate, heparan sulfate
proteoglycan, and signal sequences in targeting virions and viral
glycoproteins. Neurology. 1995;45:S15-S17.
17. Abendroth A, Arvin AM. Host response to primary infection.
In: Arvin AM, Gershon A, eds. Varicella-Zoster Virus: Virology and
Clinical Management. Cambridge: Cambridge University Press;
2000:142-156.
18. Abendroth A, Arvin A. Immune evasion mechanisms of varicella-zoster
virus.
Arch Virol Suppl. 2001;17:99-107.
[PubMed: 11339556]
19. Abendroth A, Lin I, Slobedman B, Ploegh H, Arvin A. Varicella-zoster
virus retains major histocompatibility complex class I proteins
in the Golgi compartment of infected cells.
J Virol. 2001;75:4878-4888.
[PubMed: 11312359]
20. Abendroth A, Slobedman B, Lee E, Mellins E, Wallace M, Arvin
AM. Modulation of major histocompatibility class II protein expression
by varicella-zoster virus. J Virol. 2000;74(4):1900-1907.
21. Cohen J. Infection of cells with varicella-zoster virus
down-regulates surface expression of class I major histocompatibility
complex antigens.
J Infect Dis. 1998;177:1390-1393.
[PubMed: 9593031]
22. Bernstein HH, Rothstein EP, Watson BM, et al. Clinical survey of
natural varicella compared with breakthrough varicella after immunization
with live attenuated Oka/Merck varicella vaccine.
Pediatrics.
1993;92:833-837.
[PubMed: 8233746]
23. Forghani B. Laboratory diagnosis of infection. In: Arvin
AM, Gershon AA, eds. Varicella-Zoster Virus: Virology and
Clinical Management. Cambridge: Cambridge University Press;
2000:351-382.
24. Dunkle LM, Arvin A, Whitley R, et al. A controlled trial
of oral
acyclovir for chickenpox in normal children.
N Engl
J Med. 1991;325:1539-1544.
[PubMed: 1944438]
25. Balfour HH, Rotbart H, Feldman S, et al.
Acyclovir treatment of
varicella in otherwise healthy adolescents.
J Pediatr. 1992;120:627-633.
[PubMed: 1313098]
26. Wallace MR, Bowler WA, Murray NB, Brodine SK, Oldfield EC.
Treatment of adult varicella with oral
acyclovir: a randomized, placebo-controlled
trial.
Ann Intern Med. 1992;117:358-363.
[PubMed: 1323943]
27. Cameron JC, Allan G, Johnston F, Finn A, Heath PT, Booy
R. Severe complications of chickenpox in hospitalized children in
the UK and Ireland. Arch Dis Child. 2007;92(12):1062-1066.
28. Laupland KB, Davies HD, Low DE, Schwartz B, Green K, McGeer
A. Invasive group A streptococcal disease in children and association
with varicella-zoster virus infection. Ontario Group A Streptococcal
Study Group. Pediatrics. 2000; 105(5):E60.
29. Mohsen AH, McKendrick M. Varicella pneumonia in adults.
Eur Respir J. 2003;21(5):886-891.
30. Steiner I, Kennedy PG, Pachner AR. The neurotropic herpes
viruses: herpes simplex and varicella-zoster. Lancet Neurol. 2007;6(11):1015-1028.
31. Guess HA, Broughton DD, Melton LJ, Kurland L. Population-based
studies of varicella complications. Pediatrics.
1986;78(suppl):723-727.
32. Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger
LB. Reyeís syndrome in the United States from 1981 through 1997. N
Engl J Med. 1999;340(18):1377-1382.
33. Lesko SM, O’Brien KL, Schwartz B, Vezina R, Mitchell AA.
Invasive group A streptococcal infection and nonsteroidal anti-inflammatory
drug use among children with primary varicella. Pediatrics.
2001;107(5):1108-1115.
34. Feldman S, Hughes W, Daniel C. Varicella in children with
cancer: 77 cases. Pediatrics. 1975; 80:388-397.
35. Derryck A, LaRussa P, Steinberg S, Capasso M, Pitt J, Gershon AA.
Varicella and zoster in children with human immunodeficiency virus
infection. Pediatr Infect Dis J. 1998;17(10):931-933.
36. Judd A, Doerholt K, Tookey PA, et al. Morbidity, mortality, and
response to treatment by children in the United Kingdom and Ireland
with perinatally acquired HIV infection during 1996–2006: planning
for teenage and adult care. Clin Infect Dis. 2007;45(7):918-924.
37. Wood SM, Shah SS, Steenhoff AP, Rutstein RM. Primary varicella
and herpes zoster among HIV-infected children from 1989 to 2006. Pediatrics.
2008;121(1):e150-e156.
38. Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of
varicella: recommendations of the Advisory Committee on Immunization
Practices (ACIP). MMWR Recomm Rep. 2007; 56(RR-4):1-40.
39. Son M, Shapiro E, LaRussa P, et al. Vaccination of children
with perinatal HIV infection protects against varicella and zoster.
Paper presented at Pediatric Academic Societies annual meeting;
2008; Honolulu, HI.
40. Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh
M. Consequences of varicella and herpes zoster in pregnancy: prospective
study of 1739 cases. Lancet. 1994;343(8912):1548-1551.
41. Harger JH, Ernest JM, Thurnau GR, et al. Frequency of congenital
varicella syndrome in a prospective cohort of 347 pregnant women. Obstet
Gynecol. 2002;100(2):260-265.
42. Enders G, Miller E. Varicella and herpes zoster in pregnancy and
the newborn. In: Arvin AM, Gershon AA, eds. Varicella-Zoster
Virus: Virology and Clinical Management. Cambridge: Cambridge
University Press; 2000:317-347.
43. Sharrar RG, LaRussa P, Galea S, et al. The postmarketing
safety profile of varicella vaccine. Vaccine. 2001;19:916-923.
44. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA.
The incidence of herpes zoster in a United States administrative
database. J Gen Intern Med. 2005;20(8):748-753.
45. Gershon AA. Zoster in immunosuppressed patients. In: Watson CPN,
Gershon A, eds. Herpes Zoster and Postherpetic Neuralgia.
Amsterdam: Elsevier; 2001:107-117.
46. Hope-Simpson RE. The nature of herpes zoster: a long term
study and a new hypothesis.
Proc Roy Soc Med. 1965;58:9-20.
[PubMed: 14267505]
47. Chen J, Gershon A, Silverstein SJ, Li ZS, Lungu O, Gershon
MD. Latent and lytic infection of isolated guinea pig enteric and
dorsal root ganglia by varicella zoster virus. J Med Virol.
2003;70:S71-S78.
48. Lungu O, Panagiotidis C, Annunziato P, Gershon A, Silverstein
S. Aberrant intracellular localization of varicella-zoster virus
regulatory proteins during latency.
Proc Natl Acad Sci U
S A. 1998;95:7080-7085.
[PubMed: 9618542]
49. Lungu O, Annunziato P, Gershon A, et al. Reactivated and
latent varicella-zoster virus in human dorsal root ganglia.
Proc
Natl Acad Sci U S A. 1995;92:10980-10984.
[PubMed: 7479921]
50. Gourishankar S, McDermid JC, Jhangri GS, Preiksaitis JK. Herpes
zoster infection following solid organ transplantation: incidence,
risk factors and outcomes in the current immunosuppressive era. Am
J Transplant. 2004;4(1):108-115.
51. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for
the management of herpes zoster. Clin Infect Dis.
2007;44(suppl 1):S1-S26.